Investors
and Media
News Releases
-
May 24, 2018
SOUTH SAN FRANCISCO, Calif., May 24, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the company has received a $100 million milestone payment from...
-
May 9, 2018-- Conference Call Today at 4:30 p.m. ET --
SOUTH SAN FRANCISCO, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today reported financial results for the three months ended March 31, 2018 and provided...
May 3, 2018– Breakthrough Product is a Major Advance in the Treatment of Patients Hospitalized with Life-Threatening Bleeding –SOUTH SAN FRANCISCO, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the U.S. Food and Drug Administration (FDA) has approved Andexxa®...
-
Apr 30, 2018
SOUTH SAN FRANCISCO, Calif., April 30, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that it will host a webcast and conference call to discuss the...
-
Apr 25, 2018– Novel Oral SYK/JAK Inhibitor for Relapsed/Refractory B-cell and T-cell Cancers –
SOUTH SAN FRANCISCO, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that new interim results from the Company’s ongoing Phase 2a study...